This independent series comprised 33 GBMs from the Salpêtrière database treated with the combination of bevacizumab/irinotecan at recurrence and for whom the CDKN2A locus homozygous deletion and EGFR amplification status were available in the initial tumor. Here, CDKN2A is linked to neoplasm.